(Q37982850)

26 August 2017

title

Glucose control in diabetes: which target level to aim for? (English)

1 reference

26 August 2017

0 references

M Laakso

1

1 reference

26 August 2017

H Cederberg

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

13 March 2012

1 reference

Journal of Internal Medicine

26 August 2017

published in

1 reference

26 August 2017

volume

272

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

1-12

1 reference

Global and societal implications of the diabetes epidemic

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Inflamed adipose tissue, insulin resistance and vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Cardiovascular disease in diabetes: where does glucose fit in?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Heart in diabetes: a microvascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Implications of using hemoglobin A1C for diagnosing diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Translating the A1C assay into estimated average glucose values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

A1C level and future risk of diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Veterans Affairs diabetes trial--corrections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Postprandial hyperglycemia and glycemic variability: should we care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

HbA₁(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Intensive glycemic control and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02528.X

10.1111/J.1365-2796.2012.02528.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference